好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

CSF Proteomics Reveal Distinct Proteomic Profile in CNS Sarcoidosis Compared to Tuberculous Meningitis
Autoimmune Neurology
S16 - Autoimmune Neurology: Immune Profiling and Antibody Detection (2:12 PM-2:24 PM)
007

Identify key protein markers and pathways distinguishing CNS sarcoidosis (CNS-S) from Tuberculosis (TB) Meningitis using unbiased CSF proteomics.

Differential diagnosis for CNS sarcoidosis is broad, with an overlapping clinical and imaging pattern with TB meningitis. Studying distinct CSF protein changes associated with CNS sarcoidosis can provide unique insights into the pathophysiology of CSN sarcoidosis, a disease characterized by high morbidity and limited molecular understanding. 

Clinically collected, CSF samples were selected from two cohorts: 1) biopsy-supported CNS sarcoidosis in the United States and 2) tuberculosis meningitis in Uganda. Over 5000 proteins were measured using the Olink Explore HT, proximity extension assay platform. Multivariate linear regression models of protein abundance values determined differentially expressed proteins in CNS sarcoidosis compared to TB meningitis. Multiple comparisons adjusted for using the Benjamini–Hochberg method. Gene Set Enrichment Analysis identified enriched Gene Ontology pathways. Least absolute shrinkage and selection operator (LASSO) regression models were fitted to determine proteins that best discriminate between CNS sarcoidosis and TB meningitis, with performance and feature stability estimated via 1,000 bootstrap iterations.

5,398 proteins passed QC criteria and were analyzed in 58 CSF samples (CNS-S, n=34, TB Meningitis, n=24).  Overall, 128 proteins (Increased: 89, Decreased: 39) demonstrated differences in CNS sarcoidosis compared to TB meningitis after adjustment for age, sex, and CSF pleocytosis, which explained up to 52% of variance (median 36% [IQR: 31-41%] of the variance).  Gene enrichment analysis, did not illustrate difference in immune pathways, however synaptic signaling and neuronal development pathways were among the top enriched pathways.  LASSO regressions demonstrated a median AUC of 0.89 for diagnostic classification.  

CSF proteomics revealed distinct protein abundance in CSF that could discriminate between CNS sarcoidosis and TB meningitis in training models. More detailed analyses including validation datasets are essential as well as identification of protein relationships.
Authors/Disclosures
Greer Waldrop, MD (UCSF)
PRESENTER
Dr. Waldrop has nothing to disclose.
Sumanth Reddy, MD Dr. Reddy has nothing to disclose.
James Sullivan, PhD Dr. Sullivan has received personal compensation for serving as an employee of Vanqua. Dr. Sullivan has received personal compensation for serving as an employee of Vanqua Bio. Dr. Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Aliada. Dr. Sullivan has stock in Abbvie.
Arshdeep Kaur, Researcher Ms. Kaur has nothing to disclose.
Colette M. Caspar Miss Caspar has nothing to disclose.
ShiLu Vanasupa, Research Associate Ms. Vanasupa has nothing to disclose.
Kelsey Zorn Ms. Zorn has nothing to disclose.
Michelle A. Hughes, BS Ms. Hughes has nothing to disclose.
Chloe Gerungan Chloe Gerungan has nothing to disclose.
Susana Dominguez Penuela, MD Dr. Dominguez Penuela has nothing to disclose.
David Acero-Garces, MD Dr. Acero-Garces has nothing to disclose.
Munther Queisi, MD Dr. Queisi has nothing to disclose.
Darlisha Williams Darlisha Williams has nothing to disclose.
Biyue Dai The institution of Biyue Dai has received research support from National Institutes of Health.
Fiona Cresswell Fiona Cresswell has nothing to disclose.
David Meya David Meya has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for National Institutes of HEalth.
David R. Boulware, MD, MPH (University of Minnesota) The institution of David R. Boulware, MD, MPH has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sfunga. David R. Boulware, MD, MPH has received publishing royalties from a publication relating to health care. David R. Boulware, MD, MPH has received personal compensation in the range of $0-$499 for serving as a Study Section with NIH.
Barney J. Stern, MD, FAAN (Johns Hopkins Outpatient Center) Dr. Stern has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Foundation for Sarcoidosis Research. The institution of Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. Dr. Stern has received publishing royalties from a publication relating to health care.
Jeffrey M. Gelfand, MD, MS, FAAN (University of California, San Francisco) Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.
Carlos A. Pardo-Villamizar, MD (Johns Hopkins U, Med Dept of Neurology) The institution of Dr. Pardo-Villamizar has received research support from National Institutes of Health. The institution of Dr. Pardo-Villamizar has received research support from Bart McLean Fund for Neuroimmunology Research .
Michael R. Wilson, MD, FAAN (University of California San Francisco) Dr. Wilson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Wilson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ouro Medicines. Dr. Wilson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharmaceuticals. Dr. Wilson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Indapta Therapeutics. Dr. Wilson has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Delve Bio. Dr. Wilson has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Cambridge Medical Experts. Dr. Wilson has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Dunham Hallmark. Dr. Wilson has stock in Delve Bio. The institution of Dr. Wilson has received research support from Genentech / Roche. The institution of Dr. Wilson has received research support from NIH. The institution of Dr. Wilson has received research support from Novartis. The institution of Dr. Wilson has received research support from National Multiple Sclerosis Society. The institution of Dr. Wilson has received research support from Fanconi Anemia Research Foundation. The institution of Dr. Wilson has received research support from Department of Defense. The institution of Dr. Wilson has received research support from Chan Zuckerberg Initiative. The institution of Dr. Wilson has received research support from Kyverna Therapeutics. Dr. Wilson has received intellectual property interests from a discovery or technology relating to health care. Dr. Wilson has received intellectual property interests from a discovery or technology relating to health care. Dr. Wilson has received personal compensation in the range of $10,000-$49,999 for serving as a Expert Witness with US Dept of Justice.
Ahmed Abdelhak, MD (UCSF Weill Institute of Neuroscience) The institution of Dr. Abdelhak has received research support from German Multiple Sclerosis Society.